Spasticity is involuntary overactivity of muscles that occurs following upper motor neuron damage to the brain or spinal cord. Upper limb spasticity is common after stroke and can cause deformity ...

The FDA has approved Allergan’s Botox to treat lower-limb spasticity in children, further extending the use of the drug – widely used as a wrinkle treatment – in therapeutic indications.

The most commonly reported use of botulinum toxin among these cases was treatment of limb muscle spasticity associated with cerebral palsy. For Botox, doses ranged from 6.25 to 32 Units/kilogram ...

Allergan’s Botox has another clinical use after the FDA granted approval for children with upper limb spasticity. The drug was first approved clinically for upper limb spasticity in adults in ...

“This approval means that adult patients who have suffered from a stroke and are experiencing lower limb spasticity in the ankle and foot will now have a safe and effective treatment option,” explains ...

Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, announced that Health Canada approved Xeomin (incobotulinumtoxinA) for the treatment of post-stroke lower limb ...

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.

BURLINGTON, Ontario, December 17, 2024--(BUSINESS WIRE)--Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN ...